

**REMARKS**


This paper is supplemental to our filing of September 26, 2003. With this Response to Restriction Requirement and Preliminary Amendment, claims 16-77 and 96-104 have been canceled, and new claims 105-175 have been added. Support for new claims 105-175 can be found throughout Applicants' specification as filed, and more specifically at page 14, lines 9-11; page 16, lines 21-23; page 17, line 21-page 18, line 2 and page 21, lines 4-5 and lines 17-19.

In response to the Restriction Requirement mailed June 23, 2005, **Applicants have elected Group I (claims 1-15 and 78-95 and new claims 105-175) for prosecution on the merits**, with traverse. Applicants believe that new claims 105-175 should be examined with elected Group I claims, drawn to drug, bio-affecting and body treating compositions, classified in class 424, subclass 425. Thus, Applicants request examination of Group I, including claims 1-15, 78-95 and 105-175.

Applicants submit that all claims are allowable as written and respectfully request early favorable action by the Examiner. If the Examiner believes that a telephone conversation with Applicants' attorney would expedite prosecution of this application, the Examiner is cordially invited to call the undersigned attorney of record.

Date: July 21, 2005

Respectfully submitted,



Name: David J. Dykeman  
Registration No.: 46,678  
Customer No.: 29932  
Palmer & Dodge LLP  
111 Huntington Avenue  
Boston, MA 02199-7613  
Tel: 617-239-0100